This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A CONTRITE quintet of National Institutes of Health administrators have told Congress that never again will they allow fraudulent data from studies to go uncorrected and unreported in the professional literature—even if they think there is little medical or public health significance.
The occasion was a hearing held by Rep John D. Dingell (D, Mich), chair of the Subcommittee on Investigations and Oversight of the House Energy and Commerce Committee. At issue was the failure of the National Cancer Institute (NCI) to adequately disseminate to the scientific community, and especially to the participants, the finding that data regarding some patients in one center of a multicenter study of breast cancer treatment were falsified. The fact that this fabrication did not affect the findings of the study was, hearing participants agreed, no excuse.
"It is very clear that the methods used to announce the results of this misconduct were not adequate,
Marwick C. NCI Trial Hearing Elicits Vow of More Oversight. JAMA. 1994;271(18):1391. doi:10.1001/jama.1994.03510420023007